- Tim Cook Should Tell Congress to Kiss His Ass
- Biotech Stock Mailbag: Vical, Sangamo, Spectrum Pharma
- What You Wear to the Office Still Matters
- Why Keryx is Lagging But Acadia is Zooming (Hint: It's About NCE)
- Windows Ad Turns The Table On Apple
Raptor Pharmaceutical Reports First Quarter Calendar Year 2013 Financial Results
04:05PM 05/08/13

5 Stocks Under $10 Set to Surge
These under-$10 stocks look poised to trade higher from current levels.
02:08PM 05/02/13

Raptor's FDA Approval Is New Test for Orphan Drug Pricing
Will insurers pay more for a orphan disease drug only because it's more convenient?
07:51AM 05/01/13
Raptor Pharmaceutical's PROCYSBI Receives FDA Approval For The Treatment Of Nephropathic Cystinosis
U.S. commercial launch anticipated by end of Q2 2013
03:51PM 04/30/13

Most Profitable Second Quarter Biotech Stocks
A list of stock-moving biotech catalysts includes FDA drug approvals, clinical trial results and closely-followed medical meetings.
06:00AM 04/02/13

5 Stocks Under $10 Set to Soar
Traders savvy enough to follow the low-priced names and trade them with discipline and sound risk management are banking ridiculous coin on a regular basis.
01:53PM 03/07/13
5 Stocks Under $10 Set to Soar (Stockpickr $)
WINDERMERE, Fla. (Stockpickr) -- Every day on Wall Street, certain stocks trading for $10 a share or less experience massive spikes higher. Trad...
01:45PM 03/07/13

Play TheStreet's FDA Drug Approval Contest
Who will be the premier prognosticator of FDA drug approvals in 2013?
12:05PM 03/05/13
Raptor Pharmaceutical Corp. To Present At The Cowen And Company 33rd Annual Health Care Conference
05:15PM 02/26/13
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV